Immunovant: IMVT-1402 meets RA D2T endpoint but unlikely to advance in Sjögren's
FROM THE WIRE · GLOBENEWSWIRE.COM
IMVT-1402 600 mg met the primary endpoint of ACR20 response at Week 28 (92.5% vs. 75.6% placebo, p=0.0139) in Period 2 (randomized withdrawal design following open-label lead-in) of the potentially registrational trial in patients with difficult-to-treat rheumatoid arthritis…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishPositive RA result but likely halt in Sjögren's, with uncertainty on the registrational path.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01IMVT-1402 600 mg met the ACR20 endpoint at Week 28 in difficult-to-treat rheumatoid arthritis.
- 02ACR20 response was 92.5% versus 75.6% for placebo, p=0.0139.
- 03FDA discussions are planned later this year on the registrational program path.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets